Key Takeaways
Bank of Montreal has agreed to sell two of its financing businesses to Stonepeak, a strategic move aimed at improving returns and concentrating on core banking activities after the stock’s 57 percent one-year surge.
In a statement on Monday, the bank said the sale would be accretive to its capital ratios and return on equity, advancing its strategic priorities by improving capital efficiency and sharpening its focus on core markets. The transaction includes the U.S. and Canadian loan portfolios of BMO's Transportation Finance and Vendor Finance businesses.
While financial terms of the deal were not disclosed, BMO will retain a 19.9 percent equity interest in the combined businesses, enabling it to participate in their future growth under a new capital structure. The sale positions the two units for continued growth with Stonepeak, an investment firm focused on infrastructure and real assets.
For investors, the divestiture sharpens the debate over BMO's valuation. The move is designed to streamline the bank and boost shareholder returns, but it comes as valuation metrics present a mixed picture for one of Canada's largest banks.
One perspective suggests BMO remains undervalued despite its strong share performance. An excess returns analysis, which capitalizes the returns a company earns above its cost of equity, places BMO's intrinsic value at C$281.97 per share. Compared to its recent price of C$208.29, this model implies the stock is still undervalued by over 26 percent, suggesting the market has not fully priced in its ability to generate profits from its equity base.
However, a more traditional valuation metric tells a different story. BMO currently trades at a Price-to-Earnings (P/E) ratio of 17.05x. This is notably above the Banks industry average of 11.01x and a peer average of 15.52x. A "Fair Ratio" calculated by Simply Wall St, which adjusts for BMO's specific growth and risk profile, sits at 16.54x, suggesting the stock is slightly overvalued on this basis. This view is tempered by a wide range of analyst price targets, from a low of C$175 to a high of C$224.
The sale to Stonepeak is a clear step by BMO's management to optimize its portfolio and enhance returns. Yet for shareholders, the ultimate success of this strategy will depend on whether the bank's streamlined operations can deliver growth that justifies its current premium P/E multiple, or if the underlying value suggested by the excess returns model will be realized.
This article is for informational purposes only and does not constitute investment advice.
